News

Avacincaptad pegol, pegcetacoplan, and aflibercept 8mg do not increase risk of ocular hypertension and glaucoma, despite having higher volumes.

This summary of dermatology news coverage from the month of August 2025 highlights some of the most notable stories in this medical subfield.

Stay updated with the latest healthcare breakthroughs, including an FDA approval and new clinical trial data, in this week's essential news roundup.

Results from a recent trial indicated continuously decreasing risks of all forms of retinal vascular occlusion and retinal vein occlusion for 5 years after treatment.

Both trials indicated lasting visual improvements in patients treated with Ixo-vec who had previously received anti-VEGF injections.

These data from the ICONIC-LEAD study were presented at DERM 2025, highlighting the efficacy and safety of icotrokinra in patients with psoriasis.

Discover key advancements in endocrinology from July 2025, including FDA approvals and trial results.

Cholesterol in liver fat droplets has been found as a key driver of liver inflammation and fibrosis.

Cafraglutide was effective with less frequent dosing than currently available medications that target GLP-1.

Findings from the IBS in America Survey suggest IBS symptoms disrupt patients’ productivity and personal activities 19 days each month.

An interim report from the ongoing trial shows few adverse events resulting from 60 weeks of treatment with the combined AAV vector/dual-transgene cassette.

In this summary of coverage at the DERM 2025 conference, a list of notable stories highlighting acne management strategies is highlighted.

The new, bioerodible intravitreal implant, which periodically releases the tyrose kinase inhibitor vorolanib, may be capable of reducing treatment burden for at least 6 months.

Co-locating ID screening in an inpatient SUD program resulted in timely identification of and linkage to care for viral hepatitis and latent tuberculosis.

A month with few regulations instead saw significant research advancements presented at the American Society of Retina Specialists’ 2025 meeting.

In this list of the top 5 posters featured at the DERM 2025 conference, a variety of recent data are spotlighted in alopecia areata, atopic dermatitis, and other disease states.

The once-daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and demonstrated improvements in cardiovascular risk factors.

The ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.

News coverage from DERM 2025 in the field of psoriasis is highlighted in this post-conference summary.

Nester describes the evolving C3G therapeutic landscape, the value of now having pegcetacoplan to offer patients, and trial data supporting its approval.

Kratom poses serious addiction risks despite its natural appeal, misleading many into believing it's a safe alternative for pain and withdrawal relief.

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Teva’s AJOVY (fremanezumab) becomes the first CGRP antagonist approved by the FDA for pediatric patients with episodic migraine.

This summary covers a variety of notable DERM 2025 conference news highlights, specifically in the area of alopecia areata.

July delivered 9 impactful advancements across the gamut of disciplines in cardiology.

This list highlights a variety of notable DERM 2025 conference news coverage, specifically in the field of atopic dermatitis.

Clinicians explore the evolving landscape of asthma and COPD treatment, emphasizing the role of biologics and biomarkers in personalized patient care.

The larger dose exhibited better gains in best-corrected visual acuity with fewer injections during the study period.